AKT1 and fragile X syndrome: Abnormal enhancement of the ERK1⁄2 (extracellular signal-regulated kinase 1⁄2) and PI3K-Akt (Phosphoinositide 3 kinase-protein kinase B) signaling pathways has been identified in both FXS patients and FXS mouse models.